Ursodeoxycholic acid
- Generic Name
- Ursodeoxycholic acid
- Brand Names
- Reltone, Urso, Urso Forte
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40O4
- CAS Number
- 128-13-2
- Unique Ingredient Identifier
- 724L30Y2QR
- Background
Ursodeoxycholic acid (UDCA), also known as ursodiol, is a naturally-occurring bile acid that constitutes a minor fraction of the human bile acid pool. UDCA has been used to treat liver disease for decades: its first use in traditional medicine dates back more than a hundred years. UDCA was first characterized in the bile of the Chinese black bear and is form...
- Indication
Ursodeoxycholic acid is indicated for the treatment of patients with primary biliary cholangitis.
It is used for the short-term treatment of radiolucent, noncalcified gallbladder stones in patients selected for elective cholecystectomy. It is also used to prevent gallstone formation in obese patients experiencing rapid weight loss.
- Associated Conditions
- Gallstones, Primary Biliary Cholangitis
- Associated Therapies
- -
Ursodeoxycholic Acid (UDCA) for Hepatic Sarcoidosis
- Conditions
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2023-06-07
- Lead Sponsor
- Ethan Weinberg
- Target Recruit Count
- 7
- Registration Number
- NCT03602976
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Umbilical Cord Mesenchymal Stem Cells in Primary Sclerosing Cholangitis
- First Posted Date
- 2018-05-04
- Last Posted Date
- 2018-05-04
- Lead Sponsor
- Fuzhou General Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT03516006
Examination of the Metabolic Effects of Direct Bile Salt Delivery to the Ileum in Humans
- Conditions
- Interventions
- First Posted Date
- 2017-06-28
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Vanderbilt University Medical Center
- Target Recruit Count
- 2
- Registration Number
- NCT03201952
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2022-12-21
- Lead Sponsor
- Humanity and Health Research Centre
- Target Recruit Count
- 500
- Registration Number
- NCT03188146
- Locations
- 🇨🇳
Centre of non-infectious liver diseases, Beijing 302 Hospital, Beijing, China., Beijing, China
Metformin in Intrahepatic Cholestasis of Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2017-02-17
- Last Posted Date
- 2018-07-26
- Target Recruit Count
- 40
- Registration Number
- NCT03056274
Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems
- Conditions
- Interventions
- First Posted Date
- 2016-12-21
- Last Posted Date
- 2016-12-23
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT03000218
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seoul, Korea, Republic of
Brain Bioenergetics in Parkinson's Disease and Response to Repeated Oral UDCA Treatment
- First Posted Date
- 2016-11-18
- Last Posted Date
- 2022-03-22
- Lead Sponsor
- University of Minnesota
- Target Recruit Count
- 5
- Registration Number
- NCT02967250
- Locations
- 🇺🇸
Center for Magnetic Resonance Research, Minneapolis, Minnesota, United States
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
- First Posted Date
- 2016-11-17
- Last Posted Date
- 2021-09-17
- Lead Sponsor
- Beijing 302 Hospital
- Registration Number
- NCT02965911
- Locations
- 🇨🇳
Beijing 302 hospital, Beijing, China
Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2021-10-27
- Lead Sponsor
- Xiaoli Fan
- Target Recruit Count
- 53
- Registration Number
- NCT02936596
- Locations
- 🇨🇳
West China Hospital, Chengdu, Sichuan, China
Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2018-04-23
- Target Recruit Count
- 34
- Registration Number
- NCT02937012
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.